EQT-owned Gambro sells CaridianBCT

The enterprise value corresponds to a multiple of approximately 15x EBITDA and represents a partial exit of the initial investment in Gambro in 2006. Gambro is 51% controlled by EQT IV and 49% by Investor.

Following the acquisition in 2006 the investors divided the company into three separate entities, Gambro, CaridianBCT and Gambro Healthcare. In 2007, Gambro Healthcare was sold to Bridgepoint.

Since the acquisition, CaridianBCT's sales have grown by more than 10% annually, while EBITDA has almost doubled. The investors have supported the company in rolling out several new products in addition to significant R&D investments.

CaridianBCT is based in Lakewood, Colorado and develops and commercialises products that meet the needs of global customers in the blood banking, therapeutic apheresis and transfusion medicine industries.

Gambro AB is based in Stockholm and was founded in 1964. Following the transaction, Gambro's external debt will be adjusted to better suit the company as the sole remaining entity. Pro forma net debt after the sale is estimated at SEK 7.6bn. Gambro generated sales of SEK 12.2bn and EBITDA of SEK 2.4bn in 2010.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Exits
• EQT
• Sweden
• Partial sale